Targeting BAFF with belimumab is successful in normalizing B cell frequency, phenotype and functions in pSS. PubMed, Rheumatology (Oxford), 03/03/2015. (Also see Treatments for Symptoms of Sjogren's Syndrome and B Cells and T Cells)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.